The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 02, 2018

Filed:

Sep. 16, 2016
Applicant:

Dnarx, San Francisco, CA (US);

Inventors:

Robert James Debs, San Francisco, CA (US);

Timothy D. Heath, Madison, WI (US);

Chakkrapong Handumrongkul, Richmond, VA (US);

Assignee:

DNARx, San Francisco, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/00 (2006.01); A61K 31/70 (2006.01); A61K 9/127 (2006.01); C07H 21/04 (2006.01); C12N 15/63 (2006.01); A61K 48/00 (2006.01); A61K 31/19 (2006.01); A61K 31/522 (2006.01); A61K 31/573 (2006.01); A61K 38/19 (2006.01); A61K 38/48 (2006.01); C07K 16/28 (2006.01); A61K 39/395 (2006.01); C07K 16/00 (2006.01); A61K 47/69 (2017.01); C12N 15/85 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 48/0016 (2013.01); A61K 9/1272 (2013.01); A61K 31/19 (2013.01); A61K 31/522 (2013.01); A61K 31/573 (2013.01); A61K 38/193 (2013.01); A61K 38/4846 (2013.01); A61K 39/395 (2013.01); A61K 47/6911 (2017.08); A61K 48/0066 (2013.01); A61K 48/0083 (2013.01); C07K 16/00 (2013.01); C07K 16/2887 (2013.01); C12Y 304/21022 (2013.01); A61K 31/00 (2013.01); A61K 48/005 (2013.01); A61K 2039/505 (2013.01); A61K 2039/53 (2013.01); C07H 21/04 (2013.01); C07K 2317/24 (2013.01); C12N 15/85 (2013.01);
Abstract

The present invention provides compositions, systems, kits, and methods for generating expression of one or more proteins and/or biologically active nucleic acid molecules in a subject (e.g., at therapeutic levels for extended periods required to produce therapeutic effects). In certain embodiments, systems and kits are provided that comprise a first composition comprising a first amount of polycationic structures, and a second composition comprising a therapeutically effective amount of expression vectors (e.g., non-viral expression vectors not associated with liposomes) that are CpG-free or CpG-reduced, where the expression vectors comprise a first nucleic acid sequence encoding: i) a first therapeutic protein or proteins, and/or ii) a first biologically active nucleic acid molecule or molecules.


Find Patent Forward Citations

Loading…